Novel Nerve-Selective Treatment for Managing Knee Pain from Symptomatic Osteoarthritis: A Preliminary Case Series.

Authors

Murray Taverner, Mary Reynolds, Surabhi Gupta, Michael Fishman

Published in

International medical case reports journal. Volume 19. Pages 628297. Epub Aug 25, 2026.

Abstract

Between conservative treatments and total knee arthroplasty, adequate interventional pain management options for osteoarthritis of the knee (OAK) are limited. BXT-786 is a novel nerve-selective biomaterial intended to provide prolonged analgesia when delivered around the nerve branches that innervate the knee joint for use in patients with symptomatic OAK.
We conducted a nonrandomized, single-cohort, open-label pilot feasibility study at a single site in Australia (ANZCTR.org ID: ACTRN12624000250538p) between April and December 2024. The primary objective of the current study was to evaluate the safety and tolerability of BXT-786 version 3.0 in four patients with symptomatic OAK. The secondary objective was to evaluate the preliminary analgesic performance of BXT-786 in managing knee pain associated with OAK.
BXT-786 treatment showed a reduction in knee pain that was observed approximately 4 to 9 days post-procedure. Compared to the baseline, the subjects saw a 79.7% decrease in average numerical rating scale pain scores at 6 months. Anecdotal information indicated that most subjects experienced pain relief, which enabled increased mobility, improved use of the affected knee, and greater engagement in daily life activities. BXT-786 treatment did not affect motor functions or result in device-related serious adverse events.
This study demonstrates feasibility of BXT-786 version 3.0 in four patients with symptomatic OAK. The observed preliminary clinical benefit of nerve-selective treatment also supports further investigation as a potential non-systemic, non-pharmacologic, and minimally invasive intervention option for long-term pain relief.

PMID:
42668833
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.